| | | |
MetS risk
|
CC risk
|
RC risk
|
|---|
|
Genotype/Haplotype
|
Model
|
Wild type
|
AOR (95% CI)*
|
p
|
AOR (95% CI)**
|
p
|
AOR (95% CI)**
|
p
|
|---|
|
VEGF 1451C > T
|
Additive
|
CC
|
0.80 (0.61 - 1.05)
|
0.105
|
1.05 (0.79 - 1.39)
|
0.742
|
1.40 (1.03 - 1.91)
|
0.031
|
| |
Dominant
|
CC
|
0.85 (0.62 - 1.16)
|
0.295
|
1.04 (0.74 - 1.46)
|
0.813
|
1.58 (1.09 - 2.28)
|
0.015
|
| |
Recessive
|
CC
|
0.36 (0.14 - 0.96)
|
0.041
|
1.16 (0.53 - 2.57)
|
0.709
|
1.12 (0.45 - 2.80)
|
0.804
|
|
VEGF 1612G > A
|
Additive
|
GG
|
1.02 (0.76 - 1.36)
|
0.920
|
0.82 (0.59 - 1.12)
|
0.216
|
0.83 (0.58 - 1.18)
|
0.304
|
| |
Dominant
|
GG
|
1.11 (0.80 - 1.54)
|
0.521
|
0.81 (0.57 - 1.15)
|
0.239
|
0.74 (0.50 - 1.11)
|
0.149
|
| |
Recessive
|
GG
|
0.38 (0.11 - 1.33)
|
0.130
|
0.68 (0.21 - 2.21)
|
0.521
|
1.48 (0.52 - 4.19)
|
0.458
|
|
VEGF 1725G > A
|
Additive
|
GG
|
1.61 (1.06 - 2.46)
|
0.026
|
1.34 (0.83 - 2.16)
|
0.235
|
1.51 (0.90 - 2.55)
|
0.118
|
| |
Dominant
|
GG
|
1.61 (1.06 - 2.46)
|
0.026
|
1.34 (0.83 - 2.16)
|
0.235
|
1.51 (0.90 - 2.55)
|
0.118
|
| |
Recessive
|
GG
|
-
|
-
|
-
|
-
|
-
|
-
|
|
VEGF 1451C/1612G/1725G
| |
Others
|
1.14 (0.92 - 1.43)
|
0.232
|
1.04 (0.82 - 1.31)
|
0.762
|
0.87 (0.67 - 1.12)
|
0.279
|
|
VEGF 1451T/1612G/1725G
| |
Others
|
0.80 (0.61 - 1.05)
|
0.101
|
1.05 (0.79 - 1.41)
|
0.735
|
1.40 (1.03 - 1.92)
|
0.030
|
|
VEGF 1451C/1612A/1725G
| |
Others
|
0.73 (0.50 - 1.07)
|
0.111
|
0.69 (0.47 - 1.02)
|
0.066
|
0.56 (0.34 - 0.90)
|
0.017
|
|
VEGF 1451C/1612A/1725A
| |
Others
|
1.54 (1.02 - 2.34)
|
0.041
|
1.12 (0.69 - 1.80)
|
0.652
|
1.42 (0.86 - 2.36)
|
0.170
|
- Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). *AORs and p values were adjusted by age and gender. **AORs and p values were adjusted by age, gender, and MetS risk factors.
